Achieve Life Sciences, Inc. (ACHV) shareholders
Close on Nov 6, 2026Market cap $691.50MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jon Winkelried Joint filing with Tpg Gp A, LLC (12.60%), James G. Coulter (12.60%) | 13,755,160 | 12.60% | 13D (active) | Apr 17, 2025 |
| venBio Global Strategic GP V, LLC Joint filing with venBio Global Strategic Fund V, L.P. (9.99%) | 10,737,317 | 9.99% | 13D (active) | Apr 15, 2026 |
| Logos Global Management GP LLC Joint filing with Logos Global Management LP (9.99%), Arsani William (9.99%) and 5 more | 10,538,440 | 9.99% | 13G (passive) | May 11, 2026 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (9.20%), Senai Asefaw, M.D. (9.20%) and 1 more | 9,903,712 | 9.20% | 13G (passive) | Apr 17, 2026 |
| Franklin Resources, Inc. Joint filing with Franklin Advisers, Inc. (8.30%) | 8,878,942 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (6.50%), Fhmlsp, L.L.C. (6.50%) | 6,625,788 | 6.50% | 13G (passive) | Apr 17, 2026 |
| Franklin Advisers, Inc. Joint filing with Franklin Resources, Inc. (6.20%) | 6,369,252 | 6.20% | 13G (passive) amendment | Apr 30, 2026 |
| VHCP Co-Investment Holdings III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.20%), Venrock Healthcare Capital Partners EG, L.P. (5.20%) and 4 more | 5,502,064 | 5.20% | 13G (passive) | Apr 17, 2026 |
| JANUS HENDERSON GROUP Ltd. | 5,502,064 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Vivo Opportunity, LLC | 5,305,640 | 5.00% | 13G (passive) | Jul 6, 2026 |
| BlackRock, Inc. | 5,271,391 | 5.10% | 13G (passive) | Jun 30, 2026 |
| Alyeska Fund GP, LLC Joint filing with Alyeska Investment Group, L.P. (5.60%), Anand Parekh (5.60%) | 2,982,722 | 5.60% | 13G (passive) amendment | Sep 30, 2025 |
| Leen Kawas Joint filing with Propel Bio Management LLC (6.81%), Richard Kayne (6.81%) and 1 more | 2,334,176 | 6.81% | 13G (passive) | Mar 4, 2024 |
| Patrick J. Callahan III Joint filing with Patrick J. Callahan III Trust (9.50%) | 2,167,439 | 9.90% | 13G (passive) | Nov 15, 2022 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACHV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,614,836 | – | $49.72M | New | 1.08% |
| Tpg Gp A, LLC | 6,877,580 | – | $44.91M | New | 0.90% |
| venBio Partners LLC | 5,914,720 | – | $38.62M | New | 7.44% |
| Logos Global Management LP | 5,425,000 | – | $35.43M | New | 1.53% |
| BlackRock, Inc. | 5,272,017 | – | $34.43M | +4,832,657 | 0.00% |
| Franklin Resources Inc | 4,953,220 | – | $32.34M | +584,027 | 0.01% |
| Paradigm Biocapital Advisors LP | 4,951,856 | – | $32.34M | New | 0.61% |
| Vanguard Capital Management LLC | 4,140,812 | – | $27.04M | +1,936,098 | 0.00% |
| Propel Bio Management, LLC | 4,034,018 | – | $26.34M | +247,593 | 13.79% |
| Marshall Wace, Llp | 3,770,313 | – | $24.62M | +2,751,032 | 0.02% |
| State Street Corp | 2,945,526 | – | $19.23M | +2,691,069 | 0.00% |
| Vivo Capital, LLC | 2,751,032 | – | $17.96M | New | 1.64% |
| VR Adviser, LLC | 2,751,032 | – | $17.96M | New | 0.54% |
| Jupiter Topco LLC | 2,751,032 | – | $17.96M | New | 0.01% |
| Eventide Asset Management, LLC | 2,220,000 | – | $14.50M | New | 0.19% |
| Geode Capital Management, LLC | 2,062,721 | – | $13.47M | +1,439,936 | 0.00% |
| Alyeska Investment Group, L.P. | 1,925,722 | – | $12.57M | New | 0.03% |
| Simplify Asset Management Inc. | 1,432,105 | – | $9.35M | +247,593 | 0.13% |
| Wellington Management Group Llp | 1,426,915 | – | $9.32M | New | 0.00% |
| LPL Financial LLC | 902,255 | – | $5.89M | +173,807 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 111 | 83M | 48 / 36 | 14 / 17 | 65M | 3M |
| Q1 2026 | 81 | 22M | 17 / 17 | 23 / 11 | 3M | 3M |
| Q4 2025 | 77 | 23M | 24 / 24 | 13 / 10 | 9M | 2M |
| Q3 2025 | 66 | 16M | 22 / 17 | 19 / 21 | 4M | 15M |
| Q2 2025 | 65 | 26M | 19 / 22 | 14 / 26 | 16M | 4M |
| Q1 2025 | 72 | 14M | 9 / 21 | 21 / 6 | 1M | 3M |
| Q4 2024 | 70 | 16M | 11 / 27 | 12 / 4 | 1M | 1M |
| Q3 2024 | 64 | 17M | 13 / 18 | 12 / 3 | 3M | 4M |
| Q2 2024 | 56 | 19M | 24 / 14 | 8 / 9 | 5M | 2M |
| Q1 2024 | 41 | 16M | 19 / 6 | 9 / 7 | 14M | 1M |
| Q4 2023 | 29 | 3M | 3 / 11 | 8 / 9 | 0M | 1M |
| Q3 2023 | 35 | 3M | 5 / 8 | 13 / 8 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
64 funds held ACHV in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ACHV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,108,369 | – | $20.30M | 0.00% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 2,220,000 | – | $14.50M | 0.81% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,993,533 | – | $13.02M | 0.02% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 1,432,105 | – | $9.35M | 12.11% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,349,858 | – | $8.81M | 0.08% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 1,095,791 | – | $7.03M | 0.61% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 957,389 | – | $6.25M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 851,832 | – | $5.47M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 731,016 | – | $4.77M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 276,242 | – | $1.45M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 261,589 | – | $1.71M | 0.11% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 189,138 | – | $1.21M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 145,507 | – | $950.16K | 0.02% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 103,456 | – | $664.19K | 0.02% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 97,174 | – | $509.19K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Andrew D. Goldberg | CEO and President, Director | 0 | Apr 21, 2026 |
| Benjamin Halladay | Chief Financial Officer | – | Oct 6, 2026 |
| Jerry Wan | Principal Accounting Officer | 46,764 | Jan 30, 2026 |
| Mark K. Oki | Chief Financial Officer | 127,940 | Jan 30, 2026 |
| Jaime Xinos | Chief Commercial Officer | 95,286 | Jan 30, 2026 |
| Craig Donnelly | Chief Operations Officer | 52,372 | Jan 30, 2026 |
| Mark Lawrence Rubinstein | Chief Medical Officer | 39,600 | Jan 30, 2026 |
| Erik Atkisson | Chief Legal Officer | 0 | Dec 8, 2025 |
| Cindy Jacobs | President & CMO | 143,214 | Sep 8, 2025 |
| Richard Alistair Stewart | Director | 209,490 | Aug 21, 2026 |
| Reid Alexander Waldman | Director | 0 | Jul 29, 2026 |
| Christopher Nathan Martin | Director | 0 | Jul 29, 2026 |
| Thomas Sellig | Director | 0 | Jul 29, 2026 |
| Jeffrey S. Farrow | Director | 0 | Jul 29, 2026 |
| Nancy R. Phelan | Director | 0 | Jul 29, 2026 |
| Aaron Royston | Director | 0 | Jul 29, 2026 |
| Lucian Iancovici | Director | 0 | Apr 24, 2026 |
| Thomas Braxton King | Director | 455,000 | Sep 8, 2025 |
| Bridget A. Martell | Director | 0 | Jun 10, 2025 |
| Kristen B. Slaoui | Director | 0 | Jun 10, 2025 |
| Stuart Duty | Director | 0 | Jun 10, 2025 |
| Tpg Gp A, Llc | 10% owner | – | Apr 24, 2026 |
| Jon Winkelried | 10% owner | – | Apr 24, 2026 |
| James G. Coulter | 10% owner | 6,877,580 | Apr 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard Alistair Stewart Director | Aug 19, 2026 | Sale | −20,626 | $8.49 | $175.11K | 208,249 |
| Richard Alistair Stewart Chief Executive Officer, Director | Sep 18, 2025 | Sale | −129,501 | $2.92 | $378.14K | 228,875 |
| Richard Alistair Stewart Chief Executive Officer, Director | Sep 18, 2025 | Option exercise | +297,500 | – | – | 358,376 |
| Mark K. Oki Chief Financial Officer | Sep 18, 2025 | Sale | −50,060 | $2.92 | $146.18K | 127,940 |
| Mark K. Oki Chief Financial Officer | Sep 18, 2025 | Option exercise | +168,000 | – | – | 178,000 |
| Cindy Jacobs President & CMO | Sep 4, 2025 | Option exercise | +110,000 | – | – | 143,214 |
| Cindy Jacobs President & CMO | Sep 4, 2025 | Sale | −27,629 | $2.77 | $76.53K | 115,585 |
| Jerry Wan Principal Accounting Officer | Sep 4, 2025 | Option exercise | +34,100 | – | – | 46,764 |
| Jerry Wan Principal Accounting Officer | Sep 4, 2025 | Sale | −14,070 | $2.77 | $38.97K | 32,694 |
| Thomas Braxton King Director | Sep 4, 2025 | Option exercise | +455,000 | – | – | 455,000 |
| Thomas Braxton King Director | Sep 4, 2025 | Sale | −139,858 | $2.77 | $387.41K | 315,142 |
| Jaime Xinos Chief Commercial Officer | Sep 4, 2025 | Option exercise | +69,000 | – | – | 95,286 |
| Jaime Xinos Chief Commercial Officer | Sep 4, 2025 | Sale | −20,854 | $2.77 | $57.77K | 74,432 |
| Richard Alistair Stewart Chieve Executive Officer, Director | Mar 17, 2025 | Buy | +10,000 | $2.86 | $28.60K | 60,876 |
| Mark K. Oki Chief Financial Officer | Mar 17, 2025 | Buy | +10,000 | $2.89 | $28.90K | 10,000 |
| John Bencich CEO, Director | Aug 16, 2024 | Award | +5,000 | $3.67 | $18.35K | 100,636 |
| Cindy Jacobs President & CMO, Director | Aug 16, 2024 | Award | +2,660 | $3.67 | $9.76K | 33,214 |
| Jerry Wan Principal Accounting Officer | Aug 16, 2024 | Award | +2,857 | $3.67 | $10.49K | 12,664 |
| John Bencich CEO, Director | Apr 19, 2024 | Option exercise | +25,000 | – | – | 101,724 |
| John Bencich CEO, Director | Apr 19, 2024 | Tax withholding | −6,088 | $4.51 | $27.46K | 95,636 |
| Jerry Wan Principal Accounting Officer | Apr 19, 2024 | Option exercise | +5,625 | – | – | 12,057 |
| Jerry Wan Principal Accounting Officer | Apr 19, 2024 | Tax withholding | −2,250 | $4.51 | $10.15K | 9,807 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 19, 2024 | Tax withholding | −10,125 | $4.51 | $45.66K | 50,876 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 19, 2024 | Option exercise | +22,500 | – | – | 61,001 |
| Cindy Jacobs President & CMO, Director | Apr 19, 2024 | Tax withholding | −3,957 | $4.51 | $17.85K | 30,554 |
| Cindy Jacobs President & CMO, Director | Apr 19, 2024 | Option exercise | +16,250 | – | – | 34,511 |
| John Bencich CEO, Director | Mar 4, 2024 | Buy | +10,000 | $4.59 | $45.90K | 76,724 |
| Richard Alistair Stewart Executive Chairman, Director | Mar 4, 2024 | Buy | +10,000 | $4.59 | $45.90K | 38,501 |
| John Bencich CEO, Director | May 30, 2023 | Buy | +5,000 | $5.50 | $27.50K | 66,730 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2023 | Tax withholding | −2,250 | $8.29 | $18.65K | 28,501 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2023 | Option exercise | +5,000 | – | – | 30,751 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2023 | Option exercise | +1,250 | – | – | 7,101 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2023 | Tax withholding | −669 | $8.29 | $5.55K | 6,432 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2023 | Tax withholding | −609 | $8.29 | $5.05K | 18,261 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2023 | Option exercise | +2,500 | – | – | 18,870 |
| John Bencich CEO, Director | Apr 28, 2023 | Option exercise | +7,500 | – | – | 63,557 |
| John Bencich CEO, Director | Apr 28, 2023 | Tax withholding | −1,827 | $8.29 | $15.15K | 61,730 |
| Cindy Jacobs President & CMO, Director | Apr 21, 2023 | Tax withholding | −3,811 | $6.80 | $25.91K | 16,370 |
| John Bencich CEO, Director | Apr 21, 2023 | Tax withholding | −5,863 | $6.80 | $39.87K | 56,057 |
| Cindy Jacobs President & CMO, Director | Apr 21, 2023 | Option exercise | +16,250 | – | – | 20,181 |
| Cindy Jacobs President & CMO, Director | Apr 21, 2023 | Tax withholding | −4,819 | $6.80 | $32.77K | 15,362 |
| Jerry Wan Principal Accounting Officer | Apr 21, 2023 | Option exercise | +5,625 | – | – | 8,861 |
| Jerry Wan Principal Accounting Officer | Apr 21, 2023 | Tax withholding | −3,010 | $6.80 | $20.47K | 5,851 |
| John Bencich CEO, Director | Apr 21, 2023 | Tax withholding | −7,324 | $6.80 | $49.80K | 54,596 |
| John Bencich CEO, Director | Apr 21, 2023 | Option exercise | +25,000 | – | – | 61,920 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 21, 2023 | Tax withholding | −10,125 | $6.80 | $68.85K | 25,751 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 21, 2023 | Option exercise | +22,500 | – | – | 35,876 |
| John Bencich CEO, Director | Nov 18, 2022 | Buy | +22,000 | – | – | 36,920 |
| John Bencich CEO, Director | Aug 16, 2022 | Award | +3,059 | $4.37 | $13.37K | 14,920 |
| Cindy Jacobs President & CMO, Director | Aug 16, 2022 | Award | +1,817 | $4.37 | $7.94K | 3,931 |
| Jerry Wan Principal Accounting Officer | Aug 16, 2022 | Tax withholding | −266 | $4.37 | $1.16K | 3,236 |
| Jerry Wan Principal Accounting Officer | Aug 16, 2022 | Award | +2,827 | $4.37 | $12.35K | 3,502 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2022 | Tax withholding | −669 | $7.43 | $4.97K | 675 |
| Jerry Wan Principal Accounting Officer | Apr 28, 2022 | Option exercise | +1,250 | – | – | 1,344 |
| Anthony Clarke CSO | Apr 28, 2022 | Tax withholding | −250 | $7.43 | $1.86K | 3,502 |
| Anthony Clarke CSO | Apr 28, 2022 | Option exercise | +1,000 | – | – | 3,752 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2022 | Option exercise | +2,500 | – | – | 2,723 |
| Cindy Jacobs President & CMO, Director | Apr 28, 2022 | Tax withholding | −609 | $7.43 | $4.52K | 2,114 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2022 | Tax withholding | −2,250 | $7.43 | $16.72K | 13,376 |
| Richard Alistair Stewart Executive Chairman, Director | Apr 28, 2022 | Option exercise | +5,000 | – | – | 15,626 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Achieve Life Sciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 224,923 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Alistair Stewart Director | Aug 19, 2026 | 20,626 | $155.11K | Aug 19, 2026 | Corporate Action |
See a number that looks wrong?